A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Congratulations to all 2026 NSW Volunteer of the Year Nominees
We love to celebrate how special our volunteers are, and the amazing work they do for us! After being nominated for 2026 NSW Volunteer of the Year awa...
Calls for Urgent Action on Aged Care Assessment Tool
MND NSW supports MND Australia's calls for greater transparency about the outcome of the Government’s review of the Integrated Assessment Tool (I...
QALSODY (tofersen) Listed on the PBS
MND NSW and MND Australia have joined FightMND in welcoming the Australian Government's decision to list QALSODY (tofersen) on the Pharmaceutical Bene...
Top 5 Frequently Asked Questions from August 2026
A diagnosis of Motor Neurone Disease (MND) can raise many questions for the person receiving the diagnosis as well as their family, friends and suppor...